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Summary 
Fifty-eight patients with high-grade astrocytoma were treated by members of the Childrens Cancer Study 
Group in a prospective randomized trial designed to study the effectiveness of chemotherapy as an adjuvant 
to standard surgical treatment and radiotherapy. Following surgical therapy, patients were assigned random- 
ly to radiotherapy with or without chemotherapy consisting of chloroethyl-cyclohexyl nitrosourea, vincris- 
tine, and prednisone. Treatment with chemotherapy prolonged survival and event-free survival. Five-year 
event-free survival was 46% for patients in the radiotherapy and chemotherapy group, and 18% for patients 
in the radiotherapy-alone group. Five-year survival was similarly improved. The differences in outcome due 
to treatment were statistically significant after correcting for imbalances in important prognostic factors 
(event-free survival, p = 0.026; survival, p-- 0.067). The presence of mitoses or necrosis in the tumor 
specimen was associated with poorer outcome. Patients whose initial surgery was limited to biopsy, and 
patients with basal ganglia lesions, also had significantly worse outcome. Chemotherapy administered at the 
time of recurrence in a small number of patients did not produce any long-term survivors. This study is to our 
knowledge the only randomized trial to investigate effectiveness of chemotherapy in the treatment of 
high-grade astrocytoma in children. 
Introduction 
Astrocytomas represent approximately 37% of all 
childhood brain tumors and 8% of all cancers in 
young people. As a group these tumors are morph- 
ologically and biologically diverse, and conse- 
quently display various degrees of malignancy. It is 
however customary to distinguish between two 
classes of astrocytomas. Low-grade astrocytomas 
(astrocytoma grade I-II), which comprise roughly 
75% of astrocytomas in children, are usually well- 
differentiated, slow growing tumors which arise 
most frequently in the cerebellum. These are often 
treated successfully with surgery alone. In contrast, 
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high-grade astrocytomas (astrocytoma grade III-  
IV, glioblastoma multiforme), which are the most 
common brain tumors in adults, are rapidly grow- 
ing, relatively poorly differentiated tumors, fifty- 
five percent of which occur supratentoriaUy, 5% in 
the cerebellum, and 40% in the brain stem. Partial 
surgical excision of supratentorial and cerebellar 
high-grade astrocytoma is often possible, but this 
alone rarely produces adequate disease control. 
Hence, post-surgical radiation therapy is routinely 
employed. The prognosis for high-grade astrocyto- 
ma treated with surgery and radiotherapy alone is 
nevertheless poor. In general, the mean duration 
of survival following diagnosis is less than a year 
[1-5]. 
In 1976, in an attempt to improve the survival of 
children with high-grade astrocytomas, the Chil- 
drens Cancer Study Group initiated a randomized 
clinical trial, CCG-943, to study the effectiveness 
of vincristine (VCR), chlorethyl-cyclohexyl nitro- 
sourea (CCNU) and prednisone (PDN) in prolong- 
ing survival and event-free survival when added to 
standard radiation therapy. A second goal of the 
trial was to determine the effectiveness of procar- 
bazine (PCZ) to induce response in recurrent pa- 
tients. CCNU, VCR, and PCZ were chosen be- 
cause each has a different mechanism of action. 
CCNU is a small, lipid soluble drug which is able to 
cross the blood-brain barrier. Its antitumor effect is 
derived primarily through alkylation. Procarbazine 
is a monoamine oxidase inhibitor which is thought 
to behave as an alkylating agent. It also shows the 
ability to cross the blood-brain barrier. VCR acts 
by blocking mitosis with metaphase arrest, but has 
only limited ability to cross the blood-brain barrier. 
It may nevertheless be effective against portions of 
the tumor in which the blood-brain barrier is dis- 
rupted. All have shown the ability to induce tumor 
responses in one or more intracranial neoplasms 
[6-9]. Prednisone was included to minimize unde- 
sirable neurological reactions to initiation or with- 
drawal of drug therapy due to cerebral edema, and 
for the possibility that its effect on cell membrane 
permeability might enhance the action of the other 
chemotherapeutic agents. 
Methods 
Eligibility, staging, and randomization 
All newly diagnosed patients between the ages of 2 
and 21 years with biopsy confirmed intracranial 
high-grade astrocytoma (Kerhonan [10] grades II-  
III, III, III-IV, and IV) were eligible. Patients with 
primary brain stem or spinal cord lesions were not 
eligible for this study. The study was divided into 
two phases. In Phase I, following initial surgery and 
pathologic confirmation of diagnosis, eligible pa- 
tients were assigned randomly to receive either 
radiotherapy alone or radiotherapy with one year 
of chemotherapy consisting of CCNU, VCR, and 
PDN. Patients who showed evidence of disease 
progression or recurrence were eligible to enter 
Phase II and receive therapy consisting of PCZ for 
patients who had received CCNU, VCR, and PDN 
in Phase I, or CCNU, VCR, and PCZ for those 
who had received radiotherapy alone. Phase II of 
the study was included to standardize the treatment 
after first recurrence or progression of disease and 
to assess the ability of PCZ to induce a response in 
patients with recurrent disease. 
Disease status was determined on the basis of 
history, physical exam, brain scan, and operative 
findings. The use of other studies (e.g., EMI, CT, 
CSF cytology, myelogram) was at the discretion of 
the treating physician as needed for diagnosis. CT 
scans were not universally available at the begin- 
ning of the study and hence were not required, 
although staging and follow-up of many patients 
did include CT. 
Guidelines for surgical treatment encouraged as 
complete a resection as possible to provide ade- 
quate internal decompression and to reduce total 
tumor burden when this was compatible with good 
post-operative neurological function. Dexametha- 
sone was used in the pre- and post-operative period 
according to standard neurosurgical practice, but 
was to be tapered and discontinued as soon as 
possible, preferably within the first two weeks of 
therapy. Surgical checklists and surgical notes were 
reviewed centrally and patients were classified as 
having complete resection, partial resection, or 
biopsy only. 
Central pathology review was performed on all 
patients. If the original diagnosis of astrocytoma 
grade II-III or greater was not supported by the 
study reviewer, the patient was declared ineligible. 
When pathology material was not available or not 
evaluable, the patient was excluded from all ana- 
lyses. In the final review, tumors were classified as 
either anaplastic astrocytoma (AA) or glioblasto- 
ma multiforme (GBM), the primary distinction be- 
tween these being the presence in the latter of at 
least one focus of unequivocal necrosis involving 
neoplastic astrocytes [11]. Mitotic figures were con- 
sidered present if more than one mitosis was ob- 
served per ten high-power fields [12]. 
Randomization and the start of treatment were 
required within 4 weeks of surgery. An adaptive 
randomization procedure [13] was used to balance 
the two treatment groups with respect to extent of 
resection (total, partial, and biopsy) and site of 
disease (supratentorial or infratentorial). 
Radiation therapy 
Both treatment regimens included radiotherapy to 
a dose of 5250 rad in 28 fractions delivered 5 days/ 
week. This dose was reduced to 4500 rad in 28 
fractions for children 2 to 3 years of age. Radiother- 
apy guidelines specified that the whole tumor vol- 
ume, as defined by neuroradiological investigation 
and surgical exploration, plus a 4cm margin of 
'normal' brain parenchyma, would be irradiated. 
In cerebellar lesions, the lower surface of the body 
of C2 would be the field limit. A minimum field size 
of 100 cm 2 was required. For large tumors investi- 
gators often interpreted these criteria as a require- 
ment for whole brain irradiation. The tumor dose 
was defined as the mid-plane dose on the central 
axis for equally weighted parallel opposed beams, 
and as the most frequent dose in the tumor volume 
(i.e. the modal dose) for unequally weighted paral- 
lel opposed beams and for other methods of irradi- 
ation. Dose variation within the tumor volume was 
limited to within 5% of the prescribed tumor dose. 
Incremental escalation to the prescibed daily radi- 
ation dose was permitted during the first 4 days of 
treatment. The radiation beam energy was defined 
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as cobalt 60 or higher. Institutional radiation oncol- 
ogists submitted radiation therapy checklists, radi- 
ation treatment sheets and the isodose distribu- 
tions for central review. 
Phase I chemotherapy 
The experimental treatment regimen consisted of 
radiotherapy as described above with the addition 
of chemotherapy during and following radiation 
for a total treatment duration of 58 weeks. Vincris- 
tine was started within four weeks of diagnosis at 
1.5 mg/m 2 intravenously (I.V.) per week (maximum 
2mg) for six injections throughout radiotherapy. 
After an interval of four weeks following the com- 
pletion of radiation therapy, six-week chemother- 
apy cycles were initiated. Vincristine was given on 
days 1, 8 and 15 of each cycle. CCNU 100 mg/m 2 
was given by mouth (p.o.), before breakfast, on 
day 2 of each cycle. Prednisone 40 mg/m2/day in 
three divided doses was given p.o. for the first 14 
days of each cycle. Dexamethasone was not admin- 
istered concurrently with prednisone. 
Treatment of recurrent or progressive disease 
Disease progression or recurrence were defined as 
abnormal symptoms accompanied by new or dete- 
riorating neurological signs, or documented chang- 
es in neuroradiological examinations such as CT 
scan or myelogram. Investigators were urged to 
wait as long as possible until recurrent or progres- 
sive disease was indisputable before declaring a 
recurrence. 
Patients who entered Phase II of the study after 
documentation of recurrent or progressive disease 
were retreated with radiation and chemotherapy as 
follows. Patients who were treated initially with 
chemotherapy and radiation received PCZ at 
100mg/m2/day p.o. for 14 days of each six-week 
cycle for eight cycles (starting at 50 mg/m 2 in the 
first cycle and increasing by 20% in subsequent 
cycles to full dose in the absence of toxicity). Pa- 
tients who were treated initially with radiation 
alone received VCR and CCNU at the same dose 
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and schedule as in Phase I. PDN was replaced with 
PCZ at 100mg/m2/day p.o. for 14 days of each six 
week cycle (starting at 50mg/mZ/day). Therapy 
would continue for eight cycles. Patients who re- 
curred after 12 months could optionally receive 
radiation therapy to recurrence sites to a dose of 
3000 rad in 15-18 fractions. 
Statistical methods 
Analysis of patient and disease characteristics and 
treatment effect were based on event-free survival 
(EFS), the time from study entry to the first disease 
progression, disease recurrence, or death, and sur- 
vival, the time from study entry to death. EFS was 
censored at the time of last patient contact at which 
disease status could be ascertained. Survival was 
censored at the time of last patient contact. Surviv- 
al and EFS were not censored, nor were patients 
excluded from analysis, because of deviations from 
protocol therapy. Statistical hypothesis tests for 
survival and EFS were based on the logrank statis- 
tic. The P-values for treatment effect were comput- 
ed using both unstratified and stratified versions of 
the logrank test, the latter to reduce bias in the 
treatment comparison attributable to imbalances 
in important prognostic factors [14, 15]. P-values 
quoted in the text and figures are for two-sided 
tests. Product-limit (Kaplan-Meier) estimates of 
survival and event-flee survival functions are used 
in the figures and to obtain survival and EFS prob- 
abilities quoted in the text. Standard errors for the 
latter are derived from Greenwood's formula [16]. 
Follow-up data to July 1, 1986 were included in the 
analysis. This date is five years after the last patient 
entry. All analyses of treatment effects were per- 
formed both according to randomized assignment 
irrespective of treatment received, and including 
only patients who received the assigned treatment 
[17, 18]. 
Three patients who died lacked data on the time 
of recurrence and were censored for EFS. All EFS 
analyses were repeated with these patients consid- 
ered as events at the censoring time, and as events 
at the time of death. Differences between these 
analyses are discussed where appropriate. 
Results 
Between 1976 and 1981, 72 patients were enrolled 
on the CCG-943 high-grade astrocytoma study. 
Thirteen patients were subsequently declared ineli- 
gible. Three of these were previously treated or 
relapsed patients who were entered only on Phase 
II of the study; three were found not to be astrocy- 
tomas (two ependymomas, one microglial sarco- 
ma); two had insufficient material for histologic 
review; three were low-grade astrocytomas; for 
one the tumor was located in the spine at the level 
of C5-C6; and one withdrew from the study before 
treatment was started. 
Fifty-eight of 59 patients were randomized, 28 to 
receive radiotherapy and chemotherapy (RT + 
CRX), and 30 to receive radiotherapy alone (RT). 
Three patients were treated with chemotherapy 
after initial assignment to RT. One of these re- 
ceived treatment with MOPP therapy after com- 
pleting radiation. These patients were retained in 
most analyses [17, 18] as ones who were rando- 
mized to RT but switched to RT + CRX, but in 
one analysis were excluded. One of the patients in 
the chemotherapy group received Phase II chemo- 
therapy with no additional radiotherapy after an 
apparent recurrence at 9 months, which in retro- 
spect was the result of a CT artifact. This patient 
was alive and disease free at last follow-up with CT 
similar to that before and at the time of the de- 
clared recurrence, and is retained uncensored in 
the analysis. The non-randomized patient was 
treated with RT + CRX. This report will deal only 
with the 58 randomized patients from this study. 
Characteristics of the 58 patients are summa- 
rized in Table 1. The two randomized groups are 
well balanced with respect to all factors, except that 
a higher proportion of patients treated with RT 
alone are glioblastoma multiforme (p = 0.030). 
Mitosis and necrosis are correlated with the path- 
ologic classification and are therefore similarly un- 
balanced. The statistical comparison of treatment 
groups was corrected for these imbalances. 
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Analys& of patient and disease characteristics 
The results of survival and EFS analyzed by indi- 
vidual patient and disease characteristics are shown 
in Table 2. Age, sex, and race were not significantly 
associated with either survival or EFS. However, 
pathologic classification, primary site of disease, 
extent of resection, necrosis, and mitosis were sig- 
nificantly associated with both types of outcome. 
Extent of resection and site of disease were high- 
ly correlated. Surgery was limited to biopsy only in 
9.5% (4/42) of patients with hemispheric lesions 
and 0.0% (0/7) with posterior fossa lesions, as com- 
pared with 77.8% (7/9) of patients with lesions in 
the basal ganglia (p<0.001, chi-square test for ho- 
mogeneity. Diencephalic lesions are also included 
in the 'basal ganglia' category.) Both site of disease 
and extent of resection were significantly correlat- 
ed with survival and EFS (p<0.001). Survival by 
site of disease is shown in Fig. 1. Patients with 
Table 1. Distribution of patient and disease characteristics within randomized groups. Frequency (percent) 
Randomized regimen 
RT + CRX RT alone Total 
N =  28 (%) N =  30 (%) N =  58 (%) 
Treated with 
RT + CRX 28 (100) 3 (10) 31 (53) 
RT alone 0 (0) 27 (90) 27 (47) 
Age 
Under 4 years 2 (7) 3 (10) 5 (8 )  
4 to 6 years 6 (22) 8 (27) 14 (24) 
7 to 10 years 4 (14) 6 (20) 10 (17) 
Over 10 years 16 (59) 13 (43) 29 (50) 
Sex 
Male 15 (54) 17 (57) 32 (55) 
Female 13 (46) 13 (43) 26 (45) 
Race 
White 21 (75) 26 (87) 47 (81) 
Black 4 (14) 3 (10) 7 (12) 
Other 3 (11) 1 (3) 4 (7) 
Extent of resection 
Complete 3 (11) 5 (17) 8 (14) 
Partial 20 (71) 19 (63) 39 (67) 
Biopsy 5 (18) 6 (20) 11 (19) 
Pathology classification 
Anaplastic 13 (46) 5 (17) 18 (31) 
Glioblastoma multiforme 15 (54) 25 (83) 40 (69) 
Primary site of disease 
Hemisphere 20 (72) 22 (73) 42 (72) 
Posterior Fossa 4 (14) 3 (10) 7 (12) 
Basal Ganglia 4 (14) 5 (17) 9 (16) 
Mitosis 
Positive 12 (43) 22 (73) 34 (59) 
Negative 13 (46) 7 (24) 20 (34) 
Not evaluable 3 (11) 1 (3) 4 (7) 
Necrosis 
Positive 16 (57) 24 (80) 40 (69) 
Negative 10 (36) 5 (17) 15 (26) 
Not evaluable 2 (7) 1 (3) 3 (5) 
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Fig. 1. Surviva l  ( in years )  by  s i te  of  d isease .  
primary site in the basal ganglia had an extremely 
poor outcome. No difference in outcome between 
hemispheric and posterior fossa sites of disease was 
observed. Survival by extent of resection is shown 
in Fig. 2, which demonstrates that patients with 
surgery limited to biopsy had a very poor outcome. 
Patients with basal ganglia tumors were in many 
cases the same patients as those with surgery limit- 
ed to biopsy. Consequently, one cannot determine 
clearly which of these factors is a more important 
predictor of outcome. 
Pathologic classification, necrosis, and mitosis 
were also highly correlated. Although the primary 
distinction between AA and GBM is the presence 
of necrosis in the latter, in two cases other features 
of the tumor were thought to suggest a classifica- 
tion opposite to that indicated by the presence or 
Table 2. A n a l y s i s  of  surv iva l  and  even t - f r ee  surv iva l  by  pa t i en t  
and  d i sease  charac te r i s t i cs  a N = 58 
Survival Event-free survival 
P-value b P-value 
Age 0.389 0.344 
Pathology 0.012 0.019 
Primary site of disease < 0.001 < 0.001 
Extent of resection < 0.001 < 0.001 
Sex 0.109 0.122 
Race 0.430 0.628 
Necrosis c 0.034 0.049 
Mitosis d 0.058 0.078 
a See Tab le  1 for ca tegor ies .  
b Two-s ided  P-va lues  for uns t r a t i f i ed  l o g r a n k  test .  
c E x c l u d e s  3 pa t i en t s  w i t h  miss ing  data .  
d E x c l u d e s  4 pa t i en t s  w i th  miss ing  data .  
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Fig. 2. Survival  ( in years)  by  ex t en t  of  resect ion.  
absence of necrosis. Only 13.3% (2/15) of AA tu- 
mors displayed mitoses as compared with 80% (32/ 
40) of GBM tumors. In 55 tumors with data on 
mitosis and necrosis, 43 (78.2%) agreed on the 
presence or absence of these features (p<0.001, 
chi-square test for homogeneity). 
Survival by pathologic classification is shown in 
Fig. 3. Patients with glioblastoma multiforme have 
significantly shorter survival than those with ana- 
plastic astrocytoma (p = 0.012). Similar results are 
obtained when the sample is divided into groups 
based on either mitosis or necrosis. Here also one 
cannot choose one of these variables as the most 
suitable predictor of prognosis. 
Analysis of  treatment effect on outcome 
Eighteen patients in the chemotherapy group and 
25 in the radiation-only group died of progressive 
disease. Three of these were censored for EFS, two 
in the chemotherapy group and one in the radio- 
therapy group. All other patients were alive and 
presumably disease-free at last follow-up. Figs 4 
and 5 show survival and EFS by randomized treat- 
ment assignment. Five-year survival was 43% (+/ 
- 9 % )  for patients randomized to radiotherapy 
and chemotherapy, and 17% ( + / - 7 % )  for pa- 
tients randomized to radiotherapy alone. Five-year 
event-free survival was 46% ( + / -  10%) and 18% 
( + / - 7 % )  respectively. Event-free survival was 
greater numerically than survival because of the 
three censored patients mentioned above. Five- 
year EFS and survival figures changed only margin- 
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Fig. 3. Survival (in years) by review pathology classification. 
ally if patients who switched therapy after randomi- 
zation (including the MOPP-treated patient) were 
excluded, or if the three patients who were cen- 
sored for EFS were assumed to have recurred at the 
time of censoring, or at the time of death. 
The majority of treatment failures involved local 
tumor progression or recurrence, some concurrent 
with new regional or metastatic lesions. In only 
four cases did recurrent disease manifest itself by 
lesions in previously uninvolved sites alone: one 
isolated bone, one spinal, one lateral ventricular 
metastasis in a patient with primary disease local- 
ized to a cerebellar hemisphere, and one late (after 
five years) recurrence in the brain stem in a patient 
with a primary temporal lesion. 
Table 3A gives P-values for the comparison of 
randomized treatment groups. The unstratified 
comparison based on EFS was significant with 
P<0.05 whether or not patients who switched 
treatment were included. The comparison of sur- 
vival is significant at the P<0.10 level. Table 3B 
shows the results when the data were stratified by 
the important prognostic factors pathology and ex- 
tent of resection. EFS remained significant at 
P<0.05 and survival at P<0.10. When the patients 
who were censored for EFS were analyzed in the 
various ways discussed in 'Statistical Considera- 
tion', all EFS comparisons remained significant at 
P<0.05. 
Fig. 6 shows event-free survival by randomized 
assignment separately within pathology groups for 
patients who received at least a partial resection. 
The difference between treatment groups is pro- 
nounced in GBM patients. In this group, five-year 
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Fig. 4. Survival (in years) by randomized treatment assignment. 
event-free survival was 42% in patients treated 
with RT + CRX and 6% when treated with RT 
(p = 0.011). Five-year survival in this group was 
36% for RT + CRX and 5% for RT (p = 0.044). A 
benefit from chemotherapy is not observed in AA 
patients. Patients with biopsy only all failed rapidly 
regardless of treatment or histology, and are not 
shown. 
Radiotherapy review 
Radiotherapy was reviewed for 51 patients. Ade- 
quate radiotherapy data on the remaining eight 
patients could not be obtained. Eighty-two percent 
(42/51) of the reviewed patients received radiation 
doses within 10% of the nominal protocol dose. 
Nine patients received doses which deviated by 
more than 10%. Two patients had very large devia- 
tions - one patient was assigned to receive radio- 
therapy and chemotherapy but refused treatment 
partway through radiotherapy and died at 6 
months, the other died during radiotherapy. The 
radiotherapy dose distributions in the two treat- 
ment groups were comparable. A smaller propor- 
tion of patients treated with RT + CRX received 
whole brain irradiation as compared with patients 
treated with RT (11/28 vs. 15/23, p = 0.10). The 
majority of patients were treated with either 4 
MEV or Cobalt 60 equipment. None of these fac- 
tors had an apparent effect on survival or event- 
free survival analyses. 
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Phase I chemotherapy review 
Most of the 31 patients who were treated with 
Phase I chemotherapy had completed a proport ion 
of chemotherapy consistent with their time on 
Phase I. Therapy modifications or delays were re- 
ported in 19 patients. Therapy delays or omission 
of one or more drug doses were noted in 10 patients 
because of infection, in three because of decreased 
absolute neutrophil count (ANC) or platelets, and 
in two for unknown reasons. Five infections were 
observed without low blood counts: 1 osteomyel- 
itis, 2 pneumonia,  1 aseptic meningitis, 1 chicken 
pox. Vincristine doses during radiotherapy were 
interrupted for 5 weeks in one patient because of 
progressive visual loss, and were omitted in the last 
three cycles in one patient who experienced psy- 
chomotor seizures. Prednisone was omitted in one 
patient in cycles 4 through 8 during administration 
of dexamethasone,  and was discontinued after cy- 
cle 1 in a patient who could not swallow the tablets. 
Table 3. Analysis of treatment effect on survival and event-free 
survival (Entries are two-sided P-values for the logrank test) 
A. Unstratified B. Stratified a 
Survival EFS Survival EFS 
- As randomized 0.080 0.021 0.067 0.026 
(N : 58) 
- Treated as randomized 0.086 0.021 0.067 0.025 
only (N = 55) 
a Logrank test stratified by Pathology and Extent of Resection. 
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Fig. 6. Event-free survival (in years) by pathology and randomi- 
zed treatment assignment. Patients with complete+ partial 
resection only. AA, Analplastic Astrocytoma; GBM, Glioblas- 
toma Multiforme; RT, Radiation therapy alone; RT + CRX, 
Radiation therapy plus chemotherapy. 
One patient mentioned in the previous section re- 
fused all therapy after one month. 
Thirteen patients completed Phase I chemother- 
apy in an average of 57 weeks. One patient re- 
ceived an extra cycle. Eight of the 13 were alive 
without signs of recurrence or progression an aver- 
age of 6.6 years from diagnosis. Four of the remain- 
ing five showed signs of recurrence 2, 4, 17 and 59 
months after completing chemotherapy and sub- 
sequently expired, the last being a brain stem re- 
currence in a temporal anaplastic astrocytoma on 
which no post-mortem was performed. The fifth 
patient died of shunt complications at 64 months 
but was apparently free of tumor. Eighteen pa- 
tients did not complete Phase I chemotherapy; 10 
exhibited progression or recurrent disease on ther- 
apy and subsequently expired, four refused further 
protocol therapy at 2 weeks, 3 weeks, 3 months, 
and 12 months and expired at 6, 5, 8, and 32 
months. Treatment  was halted after 5 cycles in one 
patient because of abdominal pain and abnormal 
liver function tests and never resumed. This patient 
is alive and disease-free at 6.6 years. One patient 
died of progressive disease at 2 months after treat- 
ment was terminated at 1 month because of pneu- 
monia. The patient who was incorrectly declared a 
recurrence was given Phase II chemotherapy and is 
alive at 6.4 years. The patient who received 12 
cycles of MOPP therapy is alive and disease-free at 
5.6 years. 
Phase H chemotherapy 
Forty-three patients died of tumor recurrence, pro- 
gressive disease, or complications due to disease. 
The treatment after disease progression is not 
known in eight of 43; 20 received no subsequent 
treatment either because of parental refusal, or 
because of rapid deterioration which precluded 
further therapy; four were treated on CCSG new 
agents protocols (three with cisplatinum, one with 
AZQ); two received other non-protocol therapy; 
and nine were treated with Phase II therapy. Five 
who were treated initially with RT received 1, 3, 5, 
8, and 9 cycles of chemotherapy consisting of vin- 
cristine, CCNU, and procarbazine. Two exhibited 
some indication of improvement, but all subse- 
quently died of progressive disease. Mean survival 
after recurrence in these patients was 14.6 months. 
Four patients who were treated initially with RT + 
CRX received 1, 2, 2, and 3 cycles of Phase II 
therapy consisting of procarbazine alone. None of 
these patients exhibited detectable benefit from 
Phase II therapy, and all died of progressive dis- 
ease with a mean survival of 7.7 months after recur- 
rence. The difference in median post-recurrence 
survival is marginally significant (p = 0.11, permu- 
tation test). Mean post-recurrence survival in five 
patients originally treated with RT who received 
other post-recurrence treatment was 7.8 months, 
which is less than for RT patients treated with 
Phase II therapy (p = 0.087). 
Discussion 
This study demonstrates that chemotherapy con- 
sisting of CCNU, vincristine, and prednisone, 
when added to standard surgery and radiotherapy, 
may prolong event-free survival and survival of 
children with supratentorial or cerebellar high- 
grade astrocytoma. The difference in EFS and sur- 
vival between treatment groups was largest in pa- 
tients with glioblastoma multiforme with at least 
partial resection of tumor. A difference between 
treatment groups was not observed in patients with 
anaplastic astrocytoma, or in patients who under- 
went biopsy only. 
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The ability to achieve at least a partial tumor 
resection was associated with better outcome. Pa- 
tients whose surgery was limited to biopsy had 
significantly worse outcome. We found no differ- 
ence, either in event-free survival or survival, when 
patients who had undergone grossly complete re- 
sections were compared with those with partial 
resections. The primary contributing factor to the 
poor outcome of the biopsy-only patients may have 
been either the amount of tumor remaining after 
surgery, or the initial tumor size or location. We 
could not determine from our data which of these 
two factors was more important. Very large or 
deeply seated tumors can interfere with critical 
brain structures and therefore contribute to poor 
outcome. These tumors can also, by virtue of their 
size or location, limit the surgeon's ability to reduce 
tumor bulk. 
Histological features of the tumor, in particular 
the distinction between anaplastic astrocytoma and 
glioblastoma multiforme, were important determi- 
nants of prognosis in these patients. The presence 
of either necrosis or mitosis in the tumor specimen 
was associated significantly with poorer outcome. 
This finding is consistent with reports on the impor- 
tance of necrosis or mitosis as prognostic criteria in 
adult malignant glioma [11, 12, 19] and in childhood 
brain stem glioma [20]. This class of neoplasms 
displays heterogeneity in other histologic charac- 
teristics [10] which were not studied. Mitosis and 
necrosis represent two of many features which may 
be associated with degree of malignancy in these 
tumors, or to their susceptibility to chemotherapy 
or other forms of treatment. 
It is difficult to draw reliable conclusions about 
the efficacy in recurrent astrocytoma of procarba- 
zine alone or in combination with CCNU and vin- 
cristine based on the relatively few patients in the 
non-randomized, Phase II portion of this study. 
Treatment with CCNU, vincristine, and procarba- 
zine in patients initially treated with RT produced 
longer survival than other post-recurrence chemo- 
therapy. This is consistent with the belief that these 
agents are active for treatment of high-grade astro- 
cytoma. However, no long-term survivals resulted. 
Delay in chemotherapy until the time of recurrence 
is therefore not supported. 
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One should take care when interpreting the 
treatment comparison which we reported for indi- 
vidual patient subgroups. Chemotherapy signifi- 
cantly prolonged event-free survival and survival in 
patients with glioblastoma multiforme who re- 
ceived at least a partial resection of their tumor, but 
had no apparent effect in patients with anaplastic 
astrocytoma or biopsy only. This seems to imply 
that chemotherapy is only of benefit in the first 
group. There were, however, relatively few pa- 
tients in the biopsy-only and anaplastic astrocyto- 
ma patient subgroups. Furthermore, the discrimi- 
nation between biopsy-only and partially resected 
patients, or between anaplastic astrocytoma and 
glioblastoma multiforme, represents cutpoints on a 
continuum rather than unequivocal distinctions. 
Because of this it could equally be argued that 
chemotherapy may be effective to some extent in 
biopsy-only and anaplastic astrocytoma categories 
even though we did not observe an outcome differ- 
ence due to treatment. This question cannot be 
resolved from our data alone. 
CCG-943 is to our knowledge the only rando- 
mized clinical trial to investigate the effectiveness 
of chemotherapy in the treatment of high grade 
astrocytoma in children. A number of trials have 
investigated the efficacy of chemotherapy in treat- 
ing adult malignant glioma. Nine clinical trials re- 
ported between 1976 and 1985 [21-29] included 
randomized comparisons of radiotherapy with and 
without chemotherapy containing a nitrosourea 
alone or in combination with other agents. Two of 
these [21, 25] reported significant prolongation of 
survival, although in one [21] the importance of 
CCNU in the chemotherapy regimen could not be 
demonstrated clearly. In one report [22], survival 
was prolonged significantly in a subset of patients. 
In three reports [22, 28, 29], a significantly greater 
number of long-term survivors were reported in the 
chemotherapy-treated group. In the remaining 
studies, no advantage to chemotherapy when add- 
ed to radiotherapy was found. None of the trials 
reported significantly poorer survival in the chemo- 
therapy group. Stenning et al. [30] concluded from 
their thorough review that reports in the medical 
literature provide evidence that a course of nitro- 
sourea only, when added to radiotherapy, im- 
proves survival of high grade glioma patients. 
Hence, although the collective findings of the re- 
ported trials and ours are mixed, they nevertheless 
support the view that chemotherapy can improve 
survival and event-free survival in the treatment of 
intracranial high-grade astrocytoma. 
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